look into it.. how long has their trial been recruiting and how many patients have enrolled?
COVID-19 ARDS is a mine-field for anybody who wants to treat ventilated patients. MSB got a free shot at it with the NIH funding the trial.
If CYP or anyone else wants to put their own funds into that space... good luck.
MSB have had their shot, and they will get valuable data that will be used to guide their trial in a long-term opportunity in non-COVID ARDS.
Let those run the minefield and burn capital, while Mesoblast and Novartis focus on the real cash cow.
Cell Therapy News/Articles, page-8297
-
- There are more pages in this discussion • 9,731 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15990 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 48632 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |